Jefferies downgraded PeptiDream to Hold from Buy with a price target of 1,900 yen, down from 2,200 yen. The firm has become “more optimistic” about radiopharma revenues, but “less optimistic” about margins, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>